Unlearn.AI is a technology company.
Unlearn.AI has raised $115.0M across 4 funding rounds.
Unlearn.AI has raised $115.0M in total across 4 funding rounds.
Unlearn.AI has raised $115.0M in total across 4 funding rounds.
Unlearn.AI's investors include 8VC, AI4ALL, Chicago Ventures, Costanoa Ventures, Endeavor Venture Funds, Health Velocity Capital, Insight Partners, Intuitive Ventures, RA Capital, Radical Ventures, Remiges Ventures, Valspring Capital.
Unlearn.AI is a San Francisco-based technology company founded in 2017 that develops generative AI models to create digital twins of clinical trial participants, predicting individual health outcomes to optimize clinical trials.[1][2][3][6] It serves pharmaceutical sponsors, biotech companies, and academic institutions by solving key challenges in drug development, such as slow enrollment, long timelines, high costs, and ethical concerns over placebo groups, enabling faster, smaller, more efficient trials like TwinRCTs that allow more patients to receive experimental treatments.[4][6][7] With over $130M raised, including a $50M Series C in 2024, Unlearn has built a dataset of over 300,000 patients and powers trials for leading global pharma companies, with its methods qualified by the European Medicines Agency and aligned with FDA guidance.[5][6]
The company's core product—digital twin generators (DTGs)—uses longitudinal patient data from past trials and studies to simulate "what if" scenarios, forecasting outcomes under placebo conditions to enhance trial power and accelerate innovation toward precision medicine.[1][4][5]
Unlearn.AI was founded in 2017 by a team of machine learning experts led by CEO Charles Fisher, alongside co-founders Aaron and Jon, who had collaborated on the ML team at a virtual reality company after backgrounds in academic research in math and physics (Fisher also had a stint as a computational scientist at Pfizer).[3] The idea emerged from their conviction that generative models represented the future of AI; they named the company "Unlearn.AI" as a portmanteau reflecting this focus.[3] Initially exploring broad applications at the intersection of generative AI and complex systems, they adopted a lean startup approach, testing ideas like simulating gene expression and longitudinal health outcomes with early customer engagements.[3]
Pivotal traction came from excelling at predicting health trajectories, leading them to pivot to medicine: creating digital twins to model patient outcomes over time, starting with clinical trials.[3][4] Recruiting business expert Graham and advisor Cami, they shifted from general AI research to reinventing medicine, emphasizing software over biotech tools like pipettes.[2][3]
Unlearn stands out in AI-for-healthcare through its focus on generative AI for prognostic digital twins tailored to individual trial participants in randomized controlled trials (RCTs), distinguishing it from competitors like InSilicoTrials (simulation-focused) or Aetion (real-world evidence).[4] Key strengths include:
Unlearn rides the generative AI wave in healthcare, transforming medicine from an "art" reliant on trial-and-error into a predictive science amid booming demand for faster drug development post-COVID and rising trial costs (often $1B+ per drug).[1][6] Timing is ideal: AI advancements in handling complex biology data coincide with regulatory openness (e.g., FDA/EMA nods) and pharma's push for efficiency amid aging populations and chronic diseases like Alzheimer's.[1][5][6] Market forces like vast untapped longitudinal datasets and AI's scalability favor Unlearn, which builds the "ultimate clinical dataset" to train superior models.[5]
It influences the ecosystem by enabling smarter trials—reducing patient burden, accelerating therapies to market, and paving for AI-driven precision medicine—positioning it as a leader in a shift where AI eliminates inefficiencies in a $100B+ clinical research market.[4][7]
Unlearn is primed to expand its DTGs into a unified model of human health, scaling from trials to full precision medicine per its "top secret plan," fueled by recent funding for dataset growth and pharma partnerships.[2][6][9] Trends like multimodal AI, richer real-world data integration, and regulatory evolution will amplify its edge, potentially halving trial sizes industry-wide. Its influence may evolve from trial optimizer to cornerstone of AI-native drug discovery, bringing life-saving treatments faster—if it sustains data moats and validation. This mission to eliminate medicine's trial-and-error echoes its founding bet on generative AI, now revolutionizing an "impossible" field.[1][3]
Unlearn.AI has raised $115.0M across 4 funding rounds. Most recently, it raised $50.0M Series C in February 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2024 | $50.0M Series C | 8VC, AI4ALL, Chicago Ventures, Costanoa Ventures, Endeavor Venture Funds, Health Velocity Capital, Insight Partners, Intuitive Ventures, RA Capital, Radical Ventures, Remiges Ventures, Valspring Capital | |
| Apr 1, 2022 | $50.0M Series B | 8VC, Insight Partners, Intuitive Ventures, RA Capital, Remiges Ventures | |
| Nov 1, 2020 | $3.0M Series A | Chicago Ventures, Endeavor Venture Funds, Health Velocity Capital, Valspring Capital | |
| Apr 1, 2020 | $12.0M Series A | 8VC, Intuitive Ventures |